Carcinoembryonic Antigen (CEA)
Carcinoembryonic antigen (CEA), first described in 1965 by Gold and Freeman, is a tumor-associated antigen characterized as an oncofetal glycoprotein. The Healgen CEA Test is a sensitive and less complicated immunoassay of CEA. CEA was first present as a specific antigen for adenocarcinoma of the colon. More recent studies have demonstrated CEA presence in a variety of malignancies, particularly those involving ectodermal tissues of gastrointestinal or pulmonary origin. Small amounts have also been demonstrated in secretions from the colonic mucosa. Additionally, CEA-like substances have been reported in normal bile from non-icteric patients.
|Product Name||Specimen||Format||Sensitivity||Catalog No.||Certifications|
|CEA Carcinoembryonic Antigen Rapid Test||Serum/Plasma||Cassette||5 ng/ml||GECEA-302a||CE Marked, not for US market|
|Serum/Plasma||Uncut Sheet||5 ng/ml||GECEA-304a||CE Marked, not for US market|
|Whole Blood/Serum/Plasma||Cassette||5 ng/ml||GECEA-402a||CE Marked, not for US market|
|Whole Blood/Serum/Plasma||Uncut Sheet||5 ng/ml||GECEA-404a||CE Marked, not for US market|